Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)

BACKGROUND: Clinical trials have shown cardiovascular benefits and potential risks from sodium glucose cotransporter 2 inhibitors (SGLT2i). Trials may have limited ability to address individual end points or safety concerns. METHODS: We performed a population-based cohort study among patients with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Udell, Jacob A., Yuan, Zhong, Rush, Toni, Sicignano, Nicholas M., Galitz, Michael, Rosenthal, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895161/
https://www.ncbi.nlm.nih.gov/pubmed/29133607
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895161/
https://www.ncbi.nlm.nih.gov/pubmed/29133607
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031227

Ejemplares similares